Previous 10 | Next 10 |
Biotechnology/Pharmaceuticals and Healthcare providers are undervalued relative to historical averages. Healthcare equipment is the most overvalued subsector. Fast facts on IYH. This monthly article series shows a dashboard with aggregate industry metrics in healthcare. ...
Gainers: Fujian Blue Hat Interactive Entertainment Technology (BHAT) +323%. F-star Therapeutics (FSTX) +59%. Rain Therapeutics (RAIN) +43%. The9 Limited (NCTY) +36%. Vroom (VRM) +33%. MSP Recovery (MSPR) +23%. uniQure (QURE) +22%. Azure Power Global (AZRE) +22%. Valneva (VALN) +21%. Anebulo P...
After gene-therapy specialist uniQure (NASDAQ: QURE) reported positive interim results from a phase 1/2 clinical trial early Thursday, its stock surged, gaining 18.5% as of 10:54 a.m. ET. That gene therapy, AMT-130, is intended to treat Huntington's disease, and per the latest updat...
uniQure N.V. (NASDAQ:QURE) added more than 15% after the Dutch biotech announced data from a low-dose cohort of its ongoing U.S.-based Phase I/II clinical trial for gene therapy AMT-130 in the treatment of Huntington’s disease. Out of the 10 patients enrolled in the randomize...
Gainers: F-star Therapeutics (FSTX) +57%. Valneva (VALN) +23%. Nutriband (NTRB) +16%. Rain Therapeutics (RAIN) +15%. uniQure (QURE) +15%. Losers: Applied Therapeutics (APLT) -25%. Mereo BioPharma Group (MREO) -14%. Rigel Pharmaceuticals (RIGL) ...
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12 months in evaluable patients treated with AMT-13...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ: QURE), please note that all the numbers have been updated. The corrected release follows: uniQure N.V. (NASDAQ: QUR...
The pharmaceutical/biotechnology subsector has the best value and quality scores. Healthcare equipment is the most overvalued industry. IHF: a concentrated ETF in healthcare providers. 10 stocks cheaper than their peers in June. For further details see: IHF: Healthca...
A group of biotechs focused on gene therapy candidates surged on Tuesday after the FDA posted a favorable review on a β-thalassemia candidate developed by commercial-stage company Bluebird bio (NASDAQ:BLUE) ahead of an AdCom meeting later this week. The data for the marketing applicati...
The U.S. Food and Drug Administration (FDA) granted priority review to uniQure (NASDAQ:QURE) and CSL's (OTCPK:CSLLY) gene therapy etranacogene dezaparvovec (EtranaDez) to treat hemophilia B. The FDA accepted to review a biologics license application (BLA) submitted by CSL Behring, a...
News, Short Squeeze, Breakout and More Instantly...
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40 million annually ~ LEXINGTON, Mass. and AMSTERDAM, July 23, 2024 (GLOBE NEWSWIRE) -...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 2.5% to $131.38 on volume of 280,159,738 shares Maxeon Solar Technologies Ltd. (MAXN) fell 8.1% to $0.248 on volume of 217,585,873 shares Tesla Inc. (TSLA) rose 3.7% to $262.33 on volume of 159,323,492 s...